In summary, our findings demonstrate that FADS1 inhibition effectively curtails renal cancer cell proliferation in vitro as well as tumor formation in vivo, primarily through the activation of the PERK-ATF4-ATF3 axis-mediated ER stress. This evidence concerns the gene ATF4 and renal carcinoma.